Biotech Values

[exwannabe]

PANC: Bev. results for 350mg group not impressive

Many hoped this group would do better than the 300mg group, and it didn't (though, perhaps only because of absorbtion or clearance issues since the serum level was lower for the 350 group)

Also, I think many are viewing a 1.0log10 viral reduction as kind of the "mark" to hit, and now Bev is not there.

I didn't here the CC, but it seams the company is going with the "it works well for some" story, which always raises a flag (and they had no need to do this, it was a N=10 trial after all).

Might be a buy under $1?